Go Deep
Astec LifeSciences Limited
Astec LifeSciences Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Sep 2026 | 20,586 | -24.3 | 4.06 | 1.15 | 711.80 |
| Sep 2026 | 20,586 | -24.3 | 4.06 | 1.15 | 711.80 |
| Oct 2026 | 20,316 | -24.2 | 4.04 | 1.15 | 708.60 |
| Oct 2026 | 19,180 | -24.1 | 4.16 | 1.15 | 729.30 |
Astec LifeSciences Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 835,643,000.0 | 1,586,226,000.0 | 1,247,203,000.0 | 910,821,000.0 |
| Net Profit | -187,174,000.0 | -77,573,000.0 | -156,954,000.0 | -330,378,000.0 |
| EPS | -8.4 | -3.5 | -7.0 | -16.9 |
Astec LifeSciences Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 4,457,151,000.0 | 3,781,466,000.0 | 4,577,012,000.0 | 6,281,662,000.0 | — |
| Net Profit | -809,175,000.0 | -1,347,524,000.0 | -469,295,000.0 | 255,649,000.0 | — |
| EPS | -37.8 | -68.7 | -23.7 | 12.9 | — |
Astec LifeSciences Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 9,420,382,000.0 | 8,814,238,000.0 | 9,749,283,000.0 | 9,794,142,000.0 | — |
| Total Liabilities | 5,511,198,000.0 | 6,464,073,000.0 | 6,054,106,000.0 | 5,598,589,000.0 | — |
| Total Equity | 3,906,058,000.0 | 2,347,452,000.0 | 3,692,871,000.0 | 4,193,632,000.0 | — |
Owes vs Owns
Astec LifeSciences Limited owed ₹0.59 for every ₹1 it owned in Mar 2026, up from ₹0.57 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.59× | 0.73× | 0.62× | 0.57× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Astec LifeSciences Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 1.1%Receivables 26.3%Inventory 14.7%Fixed assets (tangible) 48.3%Intangible assets 2.6%Other assets 7.0%
How it's funded — Mar 2026
Short-term debt 42.3%Long-term debt 5.3%Payables 9.3%Other liabilities 1.5%Shareholders' equity 41.5%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 10.5 | 0.9 | 1.6 | 0.7 |
| Receivables | 247.7 | 147.4 | 169.0 | 154.9 |
| Inventory | 138.0 | 159.8 | 195.8 | 294.8 |
| Fixed assets (tangible) | 454.8 | 497.7 | 531.9 | 440.7 |
| Intangible assets | 24.8 | 23.4 | 19.4 | 15.9 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 66.2 | 52.1 | 57.1 | 72.3 |
| Liabilities & equity | ||||
| Short-term debt | 398.9 | 274.5 | 294.9 | 330.3 |
| Long-term debt | 50.0 | 280.0 | 199.0 | 10.9 |
| Payables | 87.7 | 81.6 | 89.3 | 177.2 |
| Other liabilities | 14.5 | 10.3 | 22.2 | 41.5 |
| Shareholders' equity | 390.9 | 235.0 | 369.5 | 419.6 |
| Net tangible assets | 365.9 | 211.3 | 349.9 | 403.5 |
Astec LifeSciences Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | -807,075,000.0 | -83,986,000.0 | 102,210,000.0 | 746,560,000.0 | — |
| Investing Activities | -43,059,000.0 | -152,303,000.0 | -1,351,814,000.0 | -1,125,074,000.0 | — |
| Financing Activities | 944,870,000.0 | 237,328,000.0 | 1,249,585,000.0 | 377,703,000.0 | — |